

# anti-PD-1/PD-L1+AOAH Antibody-Drug Conjugates for Refractory Advanced Tumors

Principal Investigator: Dr. Lanqi Gong

## Technology

Novel antibody-drug conjugates (ADCs) combining AI-designed anti-PD-1/PD-L1 antibody with AOA, a newly discovered immunomodulatory enzyme. AOA protein breaks down immunosuppressive lipids in tumors, enhancing infiltration and activation of CD8+ T cells and dendritic cells to sustain long-term immune responses.

## Stage of Development

Middle stage: Efficacy and safety validated in mice; preparing large-animal studies and Phase I trials.

## Key Advantages


- Dual immune activation (CD8+ T cells + dendritic cells)
- Over 80% tumor remission in mouse models
- Synergistic with checkpoint and cell therapies
- Low-cost production with simple storage and transport

## Opportunities

- Licensing and co-development
- Strategic investment for clinical advancement
- Start-up establishment and global partnership in the Greater Bay Area

Contact: 6217-6840

: lqgong94@hku.hk



## Intellectual Property

AOAH patent held by PI. ADC drugs validated and manufactured in partnership with WuXi Biologics. Full IP protection and scalable production pipeline are established.



HKU Med

LKS Faculty of Medicine  
The University of Hong Kong  
香港大學李嘉誠醫學院